CTXR is the ticker symbol for Citius Pharmaceuticals, Inc., a publicly traded Healthcare sector company listed on Nasdaq. 13F Pro tracks CTXR with AI-powered analysis, a 32-signal quality score, SEC EDGAR financials, insider transactions, and institutional 13F holdings — all sourced directly from public SEC filings.

Is CTXR a good stock to buy?

CTXR is tracked on 13F Pro with SEC EDGAR data, but is not currently included in our 32-signal AI quality ranking. The full company profile with financials and AI insights is at https://13fpro.ai/company/CTXR.

Where does 13F Pro source CTXR data?

All Citius Pharmaceuticals, Inc. fundamentals and ownership data come directly from SEC EDGAR. Citius Pharmaceuticals, Inc. files with the SEC under CIK 1506251. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

Citius Pharmaceuticals, Inc.(CTXR)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

Citius Pharmaceuticals, Inc. (CTXR) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. CTXR is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $0.1m in revenue and is scored on the micro-cap board instead. Based on the latest XBRL financial filings (Q2 2026), Citius Pharmaceuticals, Inc. reports quarterly revenue of $1.5M, net income of $-11.9M. Top institutional holders of CTXR by reported 13-F value include GEODE CAPITAL MANAGEMENT, VANGUARD CAPITAL MANAGEMENT, Miller Financial Services, based on the most recent SEC filings. CTXR trades on the Nasdaq exchange and files with the SEC under CIK 1506251. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CTXR daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Citius Pharmaceuticals, Inc. directly from SEC EDGAR.

Revenue

$1.5M

Net Income

$-11.9M

CTXR key financials by period

Citius Pharmaceuticals, Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
Period	Form	Revenue	Net income	Operating margin
FY 2022	10-K	$90.0K	$-33.6M	—
FY 2021	10-K	$90.0K	$-23.1M	—
FY 2020	10-K	$90.0K	$-17.5M	—
FY 2019	10-K	$90.0K	$-15.6M	—
FY 2018	10-K	$75.0K	$-12.5M	—
FY 2017	10-K	$50.0K	$-10.4M	—

Institutions holding CTXR

Institutional investors reporting a position in Citius Pharmaceuticals, Inc. on SEC Form 13F.
Institution	Shares	Value	Reported
GEODE CAPITAL MANAGEMENT	215,537	$130.3K	2026-06-30
VANGUARD CAPITAL MANAGEMENT	197,364	$119.4K	2026-06-30
Miller Financial Services	130,000	$78.6K	2026-06-30
CITADEL ADVISORS	124,910	$75.5K	2026-06-30
JANE STREET GROUP	122,837	$74.3K	2026-06-30
VANGUARD FIDUCIARY	77,755	$47.0K	2026-06-30
BlackRock	69,850	$42.2K	2026-06-30
NORTHERN	62,742	$37.9K	2026-06-30
XTX Topco Ltd	59,199	$35.8K	2026-06-30
Asset Advisory Group	59,011	$35.7K	2026-06-30

SEC EDGAR: CIK 1506251 →

Citius Pharmaceuticals, Inc.

CTXR

NasdaqSmall CapHealthcare

13F Pro Quality Score

Not in ranked universe

Below size threshold

Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $0.1M in revenue and is scored on the micro-cap board instead.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.